SCHEMBL20563262

SCHEMBL20563262

Cc1c(CCNC(=O)O)ccc(Cl)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.40
HIF1A Q16665 2/20 0.40
PLAAT3 P53816 3/20 0.40
PLAAT5 Q96KN8 3/20 0.40
PLAAT2 Q9NWW9 3/20 0.40
PLAAT4 Q9UL19 3/20 0.40
PTGS2 P35354 1/20 0.40
CNR1 P21554 3/20 0.39
CLCN2 P51788 2/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CLIC1 O00299 1/20 0.37
CXCL8 P10145 1/20 0.37
MAPT P10636 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
P2RX7 Q99572 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23114101 0.84 HPGD (0.36) HPGDHIF1APLAAT3PLAAT5PLAAT2
SCHEMBL30514411 0.81 IDO1 (0.47) HPGDALDH1A1LMNAMAPT
SCHEMBL4535306 0.78 HIF1A (0.51) HIF1APLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL23113902 0.78 HPGD (0.36) HPGDHIF1APLAAT3PLAAT5PLAAT2
SCHEMBL7186116 0.75 CXCL8 (0.47) PTGS2CLCN2CLIC1CXCL8
SCHEMBL3529974 0.75 HPGD (0.67) HPGDPLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL1180411 0.74 HIF1A (0.67) HPGDHIF1APLAAT3PLAAT5PLAAT2
SCHEMBL28753564 0.73 HPGD (0.50) HPGDHIF1APLAAT3PLAAT5PLAAT2
SCHEMBL8094360 0.72 ALOX5 (0.33)
SCHEMBL27611366 0.72 HPGD (0.49) HPGDPLAAT3PLAAT5PLAAT2PLAAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-08-01 US disclosed
EP-3625222-B1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-07-21 EP disclosed
US-20200179383-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2020-06-11 US disclosed
EP-3625222-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2020-03-25 EP disclosed
WO-2018210994-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 HPGD 283/4885HIF1A 1062/4885PLAAT3 819/4885
US-20200179383-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 HPGD 307/4885HIF1A 999/4885PLAAT3 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.